These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 19657672)

  • 21. Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer.
    Wang S; Dorsey TH; Terunuma A; Kittles RA; Ambs S; Kwabi-Addo B
    PLoS One; 2012; 7(5):e37928. PubMed ID: 22701537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study.
    Cirincione R; Lintas C; Conte D; Mariani L; Roz L; Vignola AM; Pastorino U; Sozzi G
    Int J Cancer; 2006 Mar; 118(5):1248-53. PubMed ID: 16152615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.
    Asiaf A; Ahmad ST; Malik AA; Aziz SA; Rasool Z; Masood A; Zargar MA
    Tumour Biol; 2015 Aug; 36(8):6485-96. PubMed ID: 25820821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis.
    Vasilatos SN; Broadwater G; Barry WT; Baker JC; Lem S; Dietze EC; Bean GR; Bryson AD; Pilie PG; Goldenberg V; Skaar D; Paisie C; Torres-Hernandez A; Grant TL; Wilke LG; Ibarra-Drendall C; Ostrander JH; D'Amato NC; Zalles C; Jirtle R; Weaver VM; Seewaldt VL
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):901-14. PubMed ID: 19258476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
    Caldeira JR; Prando EC; Quevedo FC; Neto FA; Rainho CA; Rogatto SR
    BMC Cancer; 2006 Mar; 6():48. PubMed ID: 16512896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of promoter hypermethylation of ERβ and RARβ2 in tumor and serum DNA in Indian breast cancer patients.
    Mirza S; Sharma G; Parshad R; Srivastava A; Gupta SD; Ralhan R
    Ann Surg Oncol; 2012 Sep; 19(9):3107-15. PubMed ID: 22451234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of promoter hypermethylation of RASSF1A, RARbeta2, BRCA1 and HOXA5 in breast cancers of Indian patients.
    Bagadi SA; Prasad CP; Kaur J; Srivastava A; Prashad R; Gupta SD; Ralhan R
    Life Sci; 2008 Jun; 82(25-26):1288-92. PubMed ID: 18538349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylation status of nine tumor suppressor genes in multiple myeloma.
    Braggio E; Maiolino A; Gouveia ME; Magalhães R; Souto Filho JT; Garnica M; Nucci M; Renault IZ
    Int J Hematol; 2010 Jan; 91(1):87-96. PubMed ID: 20037750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance.
    Trifa F; Karray-Chouayekh S; Jmaa ZB; Jmal E; Khabir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
    Med Oncol; 2013 Mar; 30(1):418. PubMed ID: 23315218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis.
    Shinozaki M; Hoon DS; Giuliano AE; Hansen NM; Wang HJ; Turner R; Taback B
    Clin Cancer Res; 2005 Mar; 11(6):2156-62. PubMed ID: 15788661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of Korean with Caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in Korean women.
    Lee JS; Lo PK; Fackler MJ; Argani P; Zhang Z; Garrett-Meyer E; Sukumar S
    Cancer Biol Ther; 2007 Jul; 6(7):1114-20. PubMed ID: 17611401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer.
    Tapia C; Zlobec I; Schneider S; Kilic E; Güth U; Bubendorf L; Kim S
    Hum Pathol; 2011 Jul; 42(7):983-90. PubMed ID: 21315418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
    Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
    BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Qualitative and quantitative promoter hypermethylation patterns of the P16, TSHR, RASSF1A and RARβ2 genes in papillary thyroid carcinoma.
    Mohammadi-asl J; Larijani B; Khorgami Z; Tavangar SM; Haghpanah V; Kheirollahi M; Mehdipour P
    Med Oncol; 2011 Dec; 28(4):1123-8. PubMed ID: 20535589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p16 promoter methylation, expression, and its association with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 subtype of breast carcinoma.
    Goyal A; Sahu RK; Kumar M; Sharma S; Qayyum S; Kaur N; Singh UR; Mehrotra R; Hedau S
    J Cancer Res Ther; 2019; 15(5):1147-1154. PubMed ID: 31603125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.